Synonyms: LCB10-0200
Compound class:
Synthetic organic
Comment: GT-1 (LCB10-0200) is a novel antibacterial compound with activity against Gram-negative bacteria [5]. Its struture, in which a siderophore (dihydroxypyridone) is conjugated to a modified aminothiazoylglycyl cephalosporin, was designed to exploit siderophore-dependent pathways for the uptake of iron across the outer membrane of Gram-negative bacteria [5-6].
|
|
References |
1. Butler MS, Henderson IR, Capon RJ, Blaskovich MAT. (2023)
Antibiotics in the clinical pipeline as of December 2022. J Antibiot (Tokyo), 76 (8): 431-473. [PMID:37291465] |
2. Halasohoris SA, Scarff JM, Pysz LM, Lembirik S, Lemmon MM, Biek D, Hannah B, Zumbrun SD, Panchal RG. (2021)
In vitro and in vivo activity of GT-1, a novel siderophore cephalosporin, and GT-055, a broad-spectrum β-lactamase inhibitor, against biothreat and ESKAPE pathogens. J Antibiot (Tokyo), 74 (12): 884-892. [PMID:34522025] |
3. Nguyen LP, Pinto NA, Vu TN, Lee H, Cho YL, Byun JH, D'Souza R, Yong D. (2020)
In Vitro Activity of a Novel Siderophore-Cephalosporin, GT-1 and Serine-Type β-Lactamase Inhibitor, GT-055, against Escherichia coli, Klebsiella pneumoniae and Acinetobacter spp. Panel Strains. Antibiotics (Basel), 9 (5). [PMID:32443875] |
4. Oh SH, Kim YR, Park HS, Oh KM, Cho YL, Kwak JH. (2021)
Antibacterial Activity of LCB10-0200 against Klebsiella pneumoniae. Antibiotics (Basel), 10 (10). [PMID:34680766] |
5. Oh SH, Park HS, Kim HS, Yun JY, Oh K, Cho YL, Kwak JH. (2017)
Antimicrobial activities of LCB10-0200, a novel siderophore cephalosporin, against the clinical isolates of Pseudomonas aeruginosa and other pathogens. Int J Antimicrob Agents, 50 (6): 700-706. [PMID:28668680] |
6. Schalk IJ. (2018)
Siderophore-antibiotic conjugates: exploiting iron uptake to deliver drugs into bacteria. Clin Microbiol Infect, 24 (8): 801-802. [PMID:29649600] |